Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Moderna sends COVID-19 booster shot for NIH testing as it hikes production targets past 2B doses
Outpatient visits largely stabilized by the end of 2020, but impacted by late COVID-19 surges
J&J’s one-shot COVID-19 vaccine snags FDA staff’s backing as panel review looms
AstraZeneca to tap global COVID vaccine supply chain to fulfill second-quarter deliveries to Europe
COVID-19 tracker: FDA staffers back J&J shot ahead of review; WHO's Covax delivers first AstraZeneca doses to Africa
UPDATED Coronavirus tracker: CVS to offer COVID vaccines in 6 more states
One in five women say they want more children now than pre-COVID, Evernorth survey finds
PPD sees 30% fourth-quarter revenue jump, beats estimates

Featured Story

Moderna sends COVID-19 booster shot for NIH testing as it hikes production targets past 2B doses

By Eric Sagonowsky

In the span of about a year, Moderna has gone from being a clinical-stage biotech with no marketed products to a key partner in the global COVID-19 vaccination effort. Now it's doubling down on its manufacturing push, with more than 2 billion doses in its sights—including plans for booster shots.

Outpatient visits largely stabilized by the end of 2020, but impacted by late COVID-19 surges

By Tina Reed

The analysis also looked at which specialties were faring the best—and the worst—compared to their pre-pandemic volumes.

J&J’s one-shot COVID-19 vaccine snags FDA staff’s backing as panel review looms

By Amirah Al Idrus

FDA staffers endorsed Johnson & Johnson's COVID-19 vaccine as safe and effective in briefing documents released (PDF) on Wednesday, ahead of an advisory committee meeting scheduled for Friday. The documents reiterated that the vaccine was 66.1% effective at preventing COVID-19 infection at least 28 days after vaccination, with “no specific safety concerns identified that would preclude issuance of an EUA.”

AstraZeneca to tap global COVID vaccine supply chain to fulfill second-quarter deliveries to Europe

By Eric Sagonowsky

Just a month ago, AstraZeneca told authorities in Europe it would fall short on its first-quarter COVID-19 vaccine deliveries, setting off a contentious few days as officials there pressed the company to amp up supplies. Now the drugmaker is raising flags about its second-quarter deliveries. But this time, it has a plan to divert doses from elsewhere.

COVID-19 tracker: FDA staffers back J&J shot ahead of review; WHO's Covax delivers first AstraZeneca doses to Africa

By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale

FDA staffers backed Johnson & Johnson's shot ahead of Friday's advisory panel review. WHO's equitable vaccine distribution effort made its first delivery outside of India. Germany is barely using the AstraZeneca vaccines it has available, the country's health ministry said. And contract research organization PPD bounced back in Q4 after after facing pandemic hurdles early last year.

COVID-19 Tracker

Featured Story

Moderna sends COVID-19 booster shot for NIH testing as it hikes production targets past 2B doses

Top Stories

Outpatient visits largely stabilized by the end of 2020, but impacted by late COVID-19 surges

J&J’s one-shot COVID-19 vaccine snags FDA staff’s backing as panel review looms

AstraZeneca to tap global COVID vaccine supply chain to fulfill second-quarter deliveries to Europe

COVID-19 tracker: FDA staffers back J&J shot ahead of review; WHO's Covax delivers first AstraZeneca doses to Africa

UPDATED Coronavirus tracker: CVS to offer COVID vaccines in 6 more states

One in five women say they want more children now than pre-COVID, Evernorth survey finds

PPD sees 30% fourth-quarter revenue jump, beats estimates